ID   HCC827-TK
AC   CVCL_E6ZQ
RX   PubMed=32163227;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Glu746_Ala750del (c.2236_2250del15); ClinVar=VCV000177620; Zygosity=Heterozygous (PubMed=32163227).
CC   Sequence variation: Mutation; HGNC; HGNC:3676; FGF2; Simple; p.Gly34Val (c.101G>T); Zygosity=Unspecified; Note=Acquired during resistance selection process (PubMed=32163227).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Val218del (c.646_648GTG[2]) (c.652_654delGTG); ClinVar=VCV000634761; Zygosity=Homozygous (from parent cell line).
CC   Omics: Genomics; Whole exome sequencing.
CC   Derived from site: In situ; Lung; UBERON=UBERON_0002048.
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2063 ! HCC827
SX   Female
AG   39Y
CA   Cancer cell line
DT   Created: 10-04-25; Last updated: 10-04-25; Version: 1
//
RX   PubMed=32163227; DOI=10.1111/1759-7714.13342; PMCID=PMC7180561;
RA   Yu T., Xia Q., Gong T., Wang J., Zhong D.-S.;
RT   "Molecular mechanism of acquired drug resistance in the EGFR-TKI
RT   resistant cell line HCC827-TR.";
RL   Thorac. Cancer 11:1129-1138(2020).
//